IGM Biosciences Inc. (IGMS) Misses Q4 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
March 26, 2020 4:06 PM EDT- Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkins lymphoma expected in the second half of 2020 -
- IND filing for IGM-8444 planned in 2020 -
- Company to host conference call today at 4:30 p.m. ET -
MOUNTAIN VIEW, Calif., March 26, 2020 (GLOBE NEWSWIRE) -- Â IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company... More
